The invention relates to the therapeutic use of oligonucleotides asimmunostimulatory agents in immunotherapy applications. More particularly, theinvention provides immunostimulatory oligonucleotides for use in methods forgenerating an immune response in a vertebrate, and for use in treating orpreventingimmune-related disorders, cancer, and other diseases or disorders. Theimmunostimulatory oligonucleotides of the invention preferably comprise novelpurines. The immunostimulatory oligonucleotides according to the inventionfurthercomprise at least two 11-mer oligonucleotides linked by glycerol at their 3'ends, andhaving a CpG moiety comprising a modified guanosine.